Eisai Co., Ltd.: Dementia trials

The registry lists 20 Dementia studies with Eisai Co., Ltd. as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 7Phase 3 7Phase 4 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid CopathologyCompletedNCT04764669Phase 2Results posted
• Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy BodiesCompletedNCT03467152Phase 2Results posted
• Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease DementiaCompletedNCT03001557Phase 2Results posted
• A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular DiseaseCompletedNCT02660983Phase 4Results posted
• Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's DiseaseTerminatedNCT02322021Phase 2Results posted
• A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension PhaseCompletedNCT01278407Phase 3Results posted
• A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type DementiaCompletedNCT01276353Phase 2Results posted
• A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy BodiesCompletedNCT00598650Phase 2Results posted
• A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)CompletedNCT00543855Phase 2Results posted
• A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male ParticipantsCompletedNCT04023877Phase 1
• Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).CompletedNCT02448784
• A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)CompletedNCT02345213Phase 4
• Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)CompletedNCT01600859Phase 1
• Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's DiseaseCompletedNCT01539031Phase 3
• A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's DiseaseCompletedNCT01404169Phase 3
• Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With DementiaCompletedNCT01327859Phase 3
• The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With DementiaCompletedNCT00165815Phase 3
• Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular DementiaCompletedNCT00165763Phase 4
• Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular DiseaseCompletedNCT00165737Phase 3
• Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's DiseaseCompletedNCT00096473Phase 3